VJHemOnc Podcast

This podcast explores the benefits and risks of screening for multiple myeloma precursor conditions like MGUS and SMM. The iStopMM and PROMISE studies are discussed, along with the clinical significance of these conditions. The impact of screening on mental health and the need for ongoing support are also highlighted.

Experts discuss the future of cell therapies in lymphoma, including chimeric antigen receptor (CAR) T-cell therapy and NK cell therapies. They highlight important data from the ELARA and BELINDA trials, and compare the role of autologous stem cell transplantation with CAR T cell therapy in treating lymphoma.

Dr. Jennifer Woyach and Adam Kittai discuss key topics in CLL treatment, including the efficacy of targeted therapies ibrutinib and venetoclax, promising alternative options like pirtobrutinib and MK1026, resistance mechanisms of BTK inhibitors, reverse wovit decay inhibitors MK1026 and ARQ531, promising molecules CDK9 inhibitor VIP152 and BCL2, BCL-XL inhibitor LP118, and the importance of undetectable minimal residual disease in CLL.

Discussion on updates and potential combinations in FLT3-mutated AML treatment from ASH 2021. Exploring the use of FLT3 inhibitors with other agents, and trial data on gilteritinib and azacitidine combination in the frontline setting. Potential benefit of combining HMA, venetoclax, gueritinib, and quizartinib for FLT3-mutated AML in the frontline, but further research needed.

Medical professionals Graham Collins and Wendy Osborne discuss exciting updates in lymphoma from the ASH annual meeting. Topics include the shift to intravenous methotrexate, frontline treatment approaches in diffuse large B cell lymphoma, cost of medicines, CAR T-cell therapy, and treatment pathways for follicular lymphoma.

The podcast discusses post-transplant maintenance therapies for FLT3+ AML, focusing on four tyrosine kinase inhibitors: sorafenib, midostaurin, gilteritinib, and quizartinib. The use of sorafenib as a maintenance therapy after allogeneic transplantation is highlighted for its efficacy in improving relapse-free and overall survival. Ongoing studies evaluate the effectiveness of the other three inhibitors, but clear evidence supporting their use is lacking.

The podcast discusses the evolving landscape of ALL treatment, including TK inhibitors and bispecific antibodies. It debates the relevance of alloHSCT in the current therapeutic landscape. The chapter explores the decision-making process for treating ALL patients and the challenges posed by CAR T cells. It also discusses therapy regimens without transplantation for Philadelphia Positive ALL patients and debates the potential avoidance of transplant in the elderly population. Additionally, a study on the use of dasatinib and blinotomer in treating ALL is discussed, showcasing high remission rates and potential for long-term remission without transplantation.

Discover the latest updates in amyloidosis treatment as discussed by Dr. Dispenseyari, including the use of daratumumab and other new therapies. Learn about the results of the Andromeda trial and the benefits of Dara cyborgine. Explore ongoing chemical trials and emerging treatments in AL amyloidosis, including antibody drug conjugate trials and BCL2 inhibition drugs.

Experts discuss key considerations for CAR-T therapy in clinical practice, including patient selection, toxicity management, and financial implications. They explore challenges and potential strategies for enhancing cellular therapies, as well as the use of gene therapy to treat globin disorders. Additionally, they highlight the limitations of CAR-T therapy in treating CLL and efforts to overcome T-cell dysfunction.

Learn about unmet needs and novel therapies for chronic myeloid leukemia (CML), including the challenges of treatment, toxicities, and emergence of resistance. Explore the potential use of an allosteric Abel1 inhibitor and the importance of targeting toxicities. Get an update on a phase 1 trial investigating a new combination therapy for CML resistant to previous treatment, which showed low response rates.